» Articles » PMID: 37762927

Serum Cytokine and MiRNA Levels Are Differently Expressed in Right- and Left-Sided Colon Cancer

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Sep 28
PMID 37762927
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor location in colorectal cancer (right- or left-sided colon cancer) is a key factor in determining disease progression. Right- and left-sided colon tumors are different in their clinical and molecular characteristics. Dysregulation of serum levels of proinflammatory cytokines, such as Transforming Growth Factor β (TGF-β) and Tumor Necrosis Factor-α (TNF-α), and Peroxisome Proliferator Activated Receptor-γ (PPAR-γ), known to be a growth-limiting and differentiation-promoting factor, as well as changes in miRNAs expression, are the major signaling pathways involved in the pathogenesis of this neoplasia. In the serum from 60 colorectal cancer (CRC) patients, we compared the differences in the expression of the levels of TGF-β, TNF-α, and PPAR-γ and in the expression of the main human miRNAs between right and left CRC. A significant over-expression in the TGF-β and TNF-α levels was observed in the serum from right-sided colon cancer patients. For the PPAR-γ, the patients with CRC located on the right-side showed lower levels than those detected in the serum from left-sided CRC subjects. Furthermore, significant differences also existed in the expression of specific circulating miRNAs between right- and left-sided CRC. In particular, the right upregulated miRNAs were all involved in the cell growth and proliferation related pathways. These findings confirm that the analysis of circulating levels of TGF-β, TNF-α, and PPAR-γ, as well as the study of the specific miRNAs in the serum, are able to identify specific characteristics of CRC patients, useful for choosing a personalized treatment protocol.

Citing Articles

Diagnostic and Prognostic Significance of a Four-miRNA Signature in Colorectal Cancer.

Gattuso G, Longo F, Spoto G, Ricci D, Lavoro A, Candido S Int J Mol Sci. 2025; 26(3).

PMID: 39940987 PMC: 11818852. DOI: 10.3390/ijms26031219.

References
1.
Johnson S, Gulhati P, Rampy B, Han Y, Rychahou P, Doan H . Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 2010; 210(5):767-76, 776-8. PMC: 2895913. DOI: 10.1016/j.jamcollsurg.2009.12.008. View

2.
Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini M . Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes. Curr Drug Targets. 2020; 22(9):998-1009. DOI: 10.2174/1389450121999201117115717. View

3.
Laha D, Grant R, Mishra P, Nilubol N . The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment. Front Immunol. 2021; 12:656908. PMC: 8110933. DOI: 10.3389/fimmu.2021.656908. View

4.
Moritani K, Hasegawa H, Okabayashi K, Ishii Y, Endo T, Kitagawa Y . Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution. Surg Today. 2013; 44(9):1685-91. PMC: 4138436. DOI: 10.1007/s00595-013-0748-5. View

5.
Bustamante-Lopez L, Nahas S, Nahas C, Pinto R, Marques C, Cecconello I . IS THERE A DIFFERENCE BETWEEN RIGHT- VERSUS LEFT-SIDED COLON CANCERS? DOES SIDE MAKE ANY DIFFERENCE IN LONG-TERM FOLLOW-UP?. Arq Bras Cir Dig. 2019; 32(4):e1479. PMC: 6918732. DOI: 10.1590/0102-672020190001e1479. View